Yu-Ligh LiouGuangdong Pharmaceutical University, China
Title: The New Concept of Gynecologic Screening and Follow-up in the COVID-19 Pandemic in China
Recent cancer statistics show that the new cases of female cancer and the mortality rate are disproportionately high. In many countries, the cancer screening programs were paused in the COVID-19 pandemic causing a screening disruption for an unknown period time. It is the right time let's rethink the true needs and values of patients in screening, repeated follow-up, over treatment and fertility preservation.
Epigenetic silencing is the driving factor of cancer progression. Significant hypermethylation were observed in endometrial cancer, ovarian cancer, cervical cancer tissue samples and cervical scraped cells. Given the substantial unmet clinical need, translational scientists are exploring the implications of epigenetic tests and treatment on the screening and treatment of gynecological tumor patients. The World Health Organization has indicated that methylation testing should be included in future cervical cancer screening guidelines, showing the importance of methylation testing.
In this speech, I will share the principle of methylation and the methylation results in cervical exfoliated cells/ tissue or blood of gynecological cancers (ovarian cancer, cervical cancer, and endometrial cancer). We also share the first evaluation data that hypermethylation of endometrial cancer of cervical scraping cells are original from endometrial cancer exfoliated cells accumulated in the cervical canal / cervix. This new evidence will provide a new non-invasive method for women who are afraid of invasive hysteroscopy, or improve the accuracy of hysteroscopy.
The high specificity and clinical advantages of methylation detection include non-invasive, self-sampling, avoiding repeated detection, prolonging the detection interval of negative results, reducing the missed diagnosis rate of gynecological cancer, etc. Methylation detection has highlighted its clinical importance during the 2019 coronavirus disease pandemic, and has attracted extensive attention from the medical community. According to the clinical data, we reconsidered the clinical application of methylation gene detection in gynecological cancers screening and follow-up.
Dr. Yu-Ligh Liou has completed his PhD at the age of 48 years from Department of Clinical Pharmacology, Xiangya Hospital, Central South University, China. He was the researcher at Clinical Precision Medicine Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University and chief of medical officer at Beijing OriginPoly Bio-Tec Co., LtD. He is committed to the clinical translational medicine of gynecological cancer (disease) detection and the development of expert consensus and guidelines in China. He has over 25 publications and has been serving as an editorial board member or reviewer of reputed Journals.